Orcel B, Delclaux B, Baud M, Derenne J P
Service de Pneumologie, Groupe Hospitalier Pitié-Salpêtrière, Paris.
Rev Mal Respir. 1993;10(1):23-8.
Three hundred fifty six patients aged 65 years or more (mean age 81.8 years) who were suffering from chronic bronchitis were included in a double-blind trial against placebo to assess the preventative effect of OM-85 BV against acute exacerbations of chronic bronchitis. OM-85 BV is an immunostimulant composed of lyophilised factions of 8 bacteria which are most frequently encountered during the course of respiratory tract infections. 291 patients completed the study. In the group treated by OM-85 BV, a significant increase in the number of patients with no episode of acute bronchitis was noted (96 versus 71, p = 0.006). There was a 38.8% reduction in the absolute numbers of episodes of acute bronchitis and a 33% reduction in the number of prescriptions for antibiotics, however there was no difference in the number of pneumonias and bronchopneumonias. These results show the protective effect of OM-85 BV against bronchial superinfections in a large population of elderly patients suffering from chronic bronchitis.
356名65岁及以上(平均年龄81.8岁)的慢性支气管炎患者被纳入一项针对安慰剂的双盲试验,以评估OM-85 BV对慢性支气管炎急性加重的预防作用。OM-85 BV是一种免疫刺激剂,由呼吸道感染过程中最常遇到的8种细菌的冻干成分组成。291名患者完成了研究。在接受OM-85 BV治疗的组中,未发生急性支气管炎发作的患者数量显著增加(96例对71例,p = 0.006)。急性支气管炎发作的绝对数量减少了38.8%,抗生素处方数量减少了33%,然而肺炎和支气管肺炎的数量没有差异。这些结果表明,OM-85 BV对大量患有慢性支气管炎的老年患者的支气管继发感染具有保护作用。